07:00 , Jul 18, 2016 |  BC Week In Review  |  Company News

Citius Pharmaceuticals sales and marketing update

Citius said it will discontinue FDA-approved Suprenza phentermine orally disintegrating tablets to treat obesity. The company noted the obesity and weight management market has “shifted” and the sympathomimetic amine anorectic “no longer meets our core...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

Tirosint levothyroxine: Postmarketing study started

Akrimax Pharmaceuticals LLC (Cranford, N.J.) began the open-label, U.S. postmarketing CONTROL trial to evaluate once-daily Tirosint in hypothyroid patients who have not previously achieved thyroid stimulating hormone levels with traditional levothyroxine tablets. Akrimax said Tirosint...
07:00 , Aug 8, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Adrenergic receptor b2 (ADRB2); ADRB3; muscarinic acetylcholine receptor M1 (CHRM1; HM1) Mouse studies suggest inhibiting autonomic nerve development in the tumor microenvironment could...
07:00 , May 28, 2012 |  BC Week In Review  |  Company News

Akrimax sales and marketing update

Akrimax launched Suprenza phentermine orally disintegrating tablets in the U.S. as a short-term adjunct to treat obesity. The wholesale acquisition cost is $45 for the 15 mg dose and $67.50 for the 30 mg dose....
07:00 , Aug 8, 2011 |  BC Week In Review  |  Company News

Akrimax management update

Akrimax Pharmaceuticals LLC , Cranford, N.J.   Business: Cardiovascular, Endocrine   Hired: Donald Olsen as president, formerly EVP of business development at Cempra Pharmaceuticals Inc.  ...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

Akrimax, NovaDel deal

Novadel received a $500,000 milestone payment from Akrimax relating to a 2009 deal granting Akrimax's Mist Acquisition LLC subsidiary an exclusive, North American license to manufacture and commercialize NirtoMist nitroglycerin spray. The milestone was triggered...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

Akrimax, NovaDel sales and marketing update

Akrimax launched NitroMist nitroglycerin lingual spray in the U.S. to treat angina pectoris or acute prophylaxis of angina pectoris due to coronary artery disease (CAD). Akrimax's Mist Acquisition LLC subsidiary has an exclusive, North American...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Company News

Mist Acquisition LLC, NovaDel deal

NovaDel received a $500,000 milestone payment from Mist under an October 2009 deal granting Mist an exclusive, North American license to manufacture and commercialize NovaDel's NitroMist nitroglycerin lingual spray to treat angina pectoris. Further details...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Company News

Akrimax, Mist Acquisition LLC, NovaDel sales and marketing update

NovaDel granted Mist an exclusive, North American license to manufacture and commercialize NovaDel's NitroMist nitroglycerin lingual spray to treat angina pectoris. Mist subsequently licensed its rights to NitroMist to Akrimax. Akrimax already markets Inderal propranolol...